

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00141		ATTY DOCKET NO. 1702.401600	APPLICATION NO. 09/674,913
APPLICANT GUSTAV GAUDERNACK, ET AL.		FILING DATE Novemb r 8, 2000	
GROUP K647 Unassigned			

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
<i>CDU</i>	WO 98/45322	10/1998	WIPO			Y s	
<i>CDU</i>	WO 97/12992	4/1997	WIPO			Y s	
<i>CDU</i>	WO 95/32731	12/1995	WIPO			Yes	
<i>CDU</i>	WO 92/14756	9/1992	WIPO			Y s	
<i>CDU</i>	WO 99/58552	11/1999	WIPO			Yes	

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>CDU</i>	van Leeuwen et al., (1998, January), Science 279:242-247, "Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients"
<i>CDU</i>	Vogel, (1998), Science 279:174, "Possible New Cause of Alzheimer's Disease Found"
<i>CDU</i>	Gaudernack, (1996), Immunotechnology 2:3-9, "T cell responses against mutant <i>ras</i> : a basis for novel cancer vaccines"
<i>CDU</i>	Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, "Ex Vivo <i>ras</i> Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study"
<i>CDU</i>	Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4 ⁺ and CD8 ⁺ T-Lymphocytes, Generated by Mutant p21- <i>ras</i> (12Val) Peptide Vaccination of a Patient, Recognize ... Tumour Cells Carrying This Mutation"
<i>CDU</i>	Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer"

EXAMINER <i>g. theil</i>	DATE CONSIDERED 11/20/2002
-----------------------------	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 2

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00141		ATTY DOCKET NO. 1702.401600		APPLICATION NO. 09/674,913	
APPLICANT GUSTAV GAUDERNACK, ET AL.		FILING DATE Nov mber 8, 2000		GROUP 16A Unassigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
CJN	Terry et al., Alzheimer Disease, 1994, pp. 179-196, "Structural Basis of the Cognitiv Alterations in Alzheimer Disease".
CJN	Barinaga, Science, vol. 257, 1992, pp. 880-881, "Getting Some 'Backbone': How MHC Binds Peptides".
CBU	Deres et al., Nature, vol. 342, 1989, pp. 561-564, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".
CJN	Tighe et al., Immun. Today, vol. 19(2), 1998, pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".

EXAMINER 	DATE CONSIDERED 11/20/2002
--------------	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2